Correction To: Association of the Matrix Metalloproteinases (Mmps) Family Gene Polymorphisms and the Risk of Coronavirus Disease 2019 (Covid-19); Implications of Contribution for Development of Neurological Symptoms in the Covid-19 Patients (Molecular Biology Reports, (2023), 50, 1, (173-183), 10.1007/S11033-022-07907-Y) Publisher Pubmed



Ramezani S¹ ; Ezzatifar F^{2, 3} ; Hojjatipour T⁴ ; Hemmatzadeh M⁵ ; Shabgah AG⁶ ; Navashenaq JG⁷ ; Aslani S⁸ ; Shomali N⁵ ; Arabi M⁹ ; Babaie F¹⁰ ; Jadidiniaragh F^{11, 12} ; Hosseinzadeh R⁸ ; Feizisani F¹³ ; Khodayar S¹⁴ Show All Authors
Source: Molecular Biology Reports Published:2023

Abstract

Correction to: Molecular Biology Reports (2023) 50:173–183. In the original form of the published article, the criteria for detection of neurologic syndrome in the COVID-19 subjects is missing. Initially, 500 subjects with COVID-19 were recruited, among which 72 patients were diagnosed as having neurologic syndrome. The diagnosis was accomplished by a neurologist using a complete examination that involved several approaches: Clinical assessment. Detailed history: Information about the patient’s medical history, including any pre-existing neurological conditions were collected. Symptom evaluation: The presence and nature of neurological symptoms, such as headache, delirium, dizziness, confusion, muscle weakness, and altered sensation were assessed. Physical examination: Neurological examination: A thorough neurological examination was performed to assess motor function, sensory function, reflexes, coordination, and cranial nerve function. Diagnostic tests: Imaging: Neuroimaging technique (brain MRI) was used to identify structural abnormalities, such as strokes, encephalitis, or other lesions. Electroencephalogram (EEG): EEG was recorded to detect abnormal brain electrical activity, such as seizures or encephalopathy. © 2023, Springer Nature B.V.